Exercise Booster Sessions in People With Multiple Sclerosis

Sponsor
University of Aarhus (Other)
Overall Status
Recruiting
CT.gov ID
NCT04913012
Collaborator
Oxford Brookes University (Other)
150
1
5
22
6.8

Study Details

Study Description

Brief Summary

This study wants to investigate whether exercise booster sessions applied in the follow-up period after an exercise intervention can increase the sustainability of exercise induced effects in persons with multiple sclerosis.

The study will be a randomized, multi-site, controlled trial. Participants will from the beginning be allocated to either aerobic training group, resistance training group or control group. After a 12 week exercise intervention, the exercise groups will be additionally randomized to receive either exercise booster sessions + standard care or just standard care in the 40 week follow up period.

It is hypothesized that exercise booster sessions can increase the sustainability of exercise induced effects.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Systematic aerobic training
  • Combination Product: Systematic resistance training
  • Combination Product: Aerobic training booster sessions
  • Combination Product: Resistance training booster sessions
N/A

Detailed Description

MS is a chronic, autoimmune, and inflammatory disease of the central nervous system, exemplified through marked demyelination and axonal loss. As a result, symptoms such as fatigue, numbness, weakness, depression, walking difficulties and spasticity frequently appear.

Although there is no cure for MS, several disease-modifying therapies are available. These can potentially slow the progression of disabilities and reduce the overall disease burden. This is of great interest from both an individual perspective, where increased disability is associated with a lowered health-related quality of life, and from a societal perspective, where increased disability is associated with larger costs.

Over the past decades exercise has been shown to be safe, tolerable and beneficial in persons with MS (PwMS). Hence, it is known to be an effective way of treating symptoms such as fatigue7, muscle weakness, walking impairments and depression. As with other chronic diseases, exercise for PwMS has been proposed as "medicine". However, in order to benefit from the positive effects of any kind of treatment (i.e. most medical drugs or exercise) one has to adhere to the prescriptions of the treatment (i.e. dose and timing). Despite all the potential benefits of exercise therapy for PwMS, one of the major challenges relate to long-term maintenance of exercise efforts.

An emerging concept that may hold the potential to increase the sustainability of exercise therapy is supervised "exercise booster sessions" (i.e. training sessions provided regularly throughout the follow-up period, to sustain effects of the preceding exercise intervention). These can be placed regularly during the follow-up period, where patients attend a number of supervised high-intensity exercise sessions, hereby trying to boost the effects of the preceding exercise intervention. Furthermore, exercise booster sessions can potentially motivate the patient to keep exercising throughout the follow up period.

However, the optimal way of utilizing this concept is still not fully understood, and has not yet been tried in neurological patients.

Therefore, the main purpose of the present study is to investigate how exercise booster sessions combined with usual care performed over a period of 40 weeks affects the sustainability of effects on functional capacity induced by a 12-week exercise intervention.

It is hypothesized that participants receiving exercise booster sessions + usual care during follow up will have a better functional capacity at follow up, than the participants receiving usual care only.

The study will be a randomized, multi-site, controlled trial. Participants will from the beginning be allocated to either aerobic training group, resistance training group or control group. After a 12 week exercise intervention, the exercise groups will be additionally randomized to receive either exercise booster sessions + standard care or just standard care in the 40 week follow up period.

The 12 week exercise intervention will consist of 2-3 weekly supervised exercise sessions. The training will be planned by exercise physiologists and performed in a progressive manner. To allow handling of a large number of participants, who is also geographically spread, the exercise intervention will be locally anchored, but at the same time supervised by student employees and controlled by internet- and telephonic communication.

Participants allocated to exercise booster sessions will receive two sessions every fifth week during the follow up period.

The power calculation is based on the primary purpose of the study which is to investigate the effect of frequently applied exercise booster sessions. To set the estimated number of participants, a two-sample two-sided power calculation has been conducted. Based on previous studies, a mean difference on functional capacity between the group receiving usual care and the group receiving exercise booster sessions + usual care, regardless of exercise intervention, is expected to be 6% with a standard deviation (SD) of ±10%.

The level of significance was set as 5% and a statistical power of 80%. According to the power calculation each group shall contain 60 participants (expected drop-out rate of 30 % is included).

The results of these studies can have great clinical implications in many ways. If we find that by adding exercise booster sessions in a follow up period, one can maintain, or maybe even improve, functional capacity over a long period, this would be a novel finding making ground for new rehabilitation opportunities

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Sustainability of Exercise Therapy by the Use of Exercise Booster Sessions in People With Multiple Sclerosis.
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Aerobic training booster group

Will receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period

Combination Product: Systematic aerobic training
Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Combination Product: Aerobic training booster sessions
Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).

Active Comparator: Aerobic training control group

Will receive 12 weeks of aerobic training followed by standard care in the 40 follow up period

Combination Product: Systematic aerobic training
Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Experimental: Resistance training booster group

Will receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period

Combination Product: Systematic resistance training
Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

Combination Product: Resistance training booster sessions
Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).

Active Comparator: Resistance training control group

Will receive 12 weeks of resistance training followed by standard care in the 40 follow up period

Combination Product: Systematic resistance training
Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

No Intervention: Control group

Will receive standard care throughout the study

Outcome Measures

Primary Outcome Measures

  1. Change in functional capacity measured as a composite score of the six minute walk test and the 5x sit to stand test (5STS). [Baseline,12 weeks and 52 weeks.]

    The six minute walk test it the distance covered during a six-minute maximal walking test. The 5STS is the time used to stand up from a chair and sit again five times.

Secondary Outcome Measures

  1. Change in functional capacity measured by the Six spot step test (SSST) [Baseline, 12 weeks and 52 weeks.]

    SSST is a measure of walking ability, balance and coordination. Measured as the time to complete the six-spot course.

  2. Change in functional capacity measured by the Multiple Sclerosis Functional Composite (MSFC) [Baseline, 12 weeks and 52 weeks.]

    Composite score from Timed 25-Feet Walk Test (T25FWT), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT)

Other Outcome Measures

  1. Change in physical activity, accelerometry [Baseline, 12 weeks and 52 weeks.]

    Measurement of level of physical activity by wearing a accelerometer for 7 days at each time point. Measured in counts/min.

  2. Change in aerobic capacity [Baseline, 12 weeks and 52 weeks.]

    Maximal oxygen uptake test on bike ergometer, measured by indirect calorimetry.

  3. Change in Multiple Sclerosis Walking Scale 12 (MSWS-12) [Baseline, 12 weeks and 52 weeks.]

    Questionnaire assessing the impact of the disease on walking. Each question is scored from 1-5 and then summed and transformed to a 0-100 scale. Higher scores indicate a greater impact on walking.

  4. Change in Modified Fatigue Impact Scale (MFIS) [Baseline, 12 weeks and 52 weeks.]

    Questionnaire assessing the effects of fatigue on physical, cognitive and psychosocial functioning. The score of the MFIS is the sum of the scores for the 21 items. A higher score represents a higher impact of fatigue, in general or in relation to one of the above mentioned areas.

  5. Change in Short Form Health Survey 36 (SF-36) [Baseline, 12 weeks and 52 weeks.]

    Questionnaire assessing health status. The SF-36 consists of eight subscales, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.

  6. Change in Hospital anxiety and depression scale (HADS) [Baseline, 12 weeks and 52 weeks.]

    Questionnaire assessing anxiety and depression. It consists of two subscales (anxiety and depression), and should be scored separately. A higher score indicates a higher degree of anxiety and depression.

  7. Change in self reported physical activity measured by the Baecke questionnaire. [Baseline, 12 weeks and 52 weeks.]

    Questionnaire assessing the self reported amount of physical activity. This questionnaire quantifies the habitual physical activity level in three indexes: occupational (at work), sport (structured exercise) and leisure (leisure time). Each index is scored from 1 to 5, with 5 indicating the highest level of physical activity

  8. Change in maximal strength [Baseline, 12 weeks and 52 weeks.]

    Maximal strength measurement measured in the knee extensors by isokinetic dynamometry.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A definite diagnosis of MS, according to the McDonald criteria

  • Walking <650m on 6MWT.

  • Exercising ≤ two sessions per week of moderate-to-high intensity during the past six months.

Exclusion Criteria:
  • Comprise comorbidities (cardiovascular-, respiratory-, orthopedic- or other neurological diseases.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aarhus University Aarhus Denmark 8000

Sponsors and Collaborators

  • University of Aarhus
  • Oxford Brookes University

Investigators

  • Principal Investigator: Laurits Taul-Madsen, MSc., University of Aarhus

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT04913012
Other Study ID Numbers:
  • Laurits_Madsen_PhD
First Posted:
Jun 3, 2021
Last Update Posted:
Nov 8, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Aarhus
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 8, 2021